Novartis News | finanzen.ch

Novartis Aktie VALOR 1200526 / ISIN CH0012005267

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

12.06.23	Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share) (GlobeNewswire)
08.06.23	Sandoz presents compelling investment proposition as standalone company at Capital Markets Day (GlobeNewswire)
02.06.23	Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups (GlobeNewswire)
01.06.23	Sandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company (GlobeNewswire)
25.05.23	Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA (GlobeNewswire)
15.05.23	New Sandoz Board of Directors appointed (GlobeNewswire)
11.05.23	Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting (GlobeNewswire)
09.05.23	Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars (GlobeNewswire)
04.05.23	Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines (GlobeNewswire)
26.04.23	Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa (GlobeNewswire)
26.04.23	Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO (GlobeNewswire)
26.04.23	Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients (GlobeNewswire)
25.04.23	Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance (GlobeNewswire)
25.04.23	Novartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose (GlobeNewswire)
20.04.23	Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis (GlobeNewswire)
03.04.23	Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation (GlobeNewswire)
31.03.23	Novartis Entresto receives positive CHMP opinion for pediatric heart failure (GlobeNewswire)
27.03.23	Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer (GlobeNewswire)
21.03.23	Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (GlobeNewswire)
20.03.23	Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset (GlobeNewswire)
16.03.23	Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer (GlobeNewswire)
09.03.23	Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines (GlobeNewswire)
07.03.23	Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut (GlobeNewswire)
07.03.23	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
20.02.23	Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors (GlobeNewswire)
22.11.22	Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH (GlobeNewswire)
07.11.22	New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years (GlobeNewswire)
07.11.22	Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics (GlobeNewswire)
25.10.22	Novartis setzt die Wachstumsdynamik fort und bestätigt die Konzernprognose für das Geschäftsjahr 2022 (GlobeNewswire)
25.10.22	Novartis maintains growth momentum and confirms FY’22 Group guidance (GlobeNewswire)
24.10.22	Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study (GlobeNewswire)
14.10.22	Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer (GlobeNewswire)
22.09.22	Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event (GlobeNewswire)
21.09.22	Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent (GlobeNewswire)
19.09.22	Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial (GlobeNewswire)
15.09.22	Novartis statement regarding competition authority investigation into assertion of a patent (GlobeNewswire)
10.09.22	Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials (GlobeNewswire)
09.09.22	Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer (GlobeNewswire)
02.09.22	Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses (GlobeNewswire)
01.09.22	Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis (GlobeNewswire)
30.08.22	Novartis presents new data in breast and prostate cancer at ESMO (GlobeNewswire)
25.08.22	Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off (GlobeNewswire)
25.08.22	Novartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten (GlobeNewswire)
15.08.22	Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer (GlobeNewswire)
25.07.22	Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA (GlobeNewswire)
21.07.22	Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF) (GlobeNewswire)
19.07.22	Novartis erzielt eine anhaltend starke Dynamik der wichtigsten Wachstumsmarken sowie Fortschritte bei strategischen Initiativen und bestätigt die Konzernprognose für das Geschäftsjahr 2022 (GlobeNewswire)
19.07.22	Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance (GlobeNewswire)
30.06.22	New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy (GlobeNewswire)
24.06.22	Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia (GlobeNewswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’833.00	0.87 %	K V
Nestle	90.24	0.78 %	K V
Roche Hldg G	296.70	0.78 %	K V
Sonova Hldg	262.80	0.42 %	K V
Kuehne+Nagel Int	206.70	0.39 %	K V
Part Grp Hldg	1’291.50	-1.45 %	K V
Logitech Intl	77.34	-1.65 %	K V
Geberit	558.20	-1.86 %	K V
ABB	46.96	-2.69 %	K V
Swisscom	513.00	-3.93 %	K V

mehr

28.03.25		Angespannte Stimmung in New York: Dow Jones fällt letztendlich
28.03.25		Freitagshandel in New York: S&P 500 gibt nachmittags nach
28.03.25		Angespannte Stimmung in New York: Dow Jones gibt nachmittags nach
28.03.25		Novartis-Aktie: FDA erteilt erweiterte Zulassung für Krebsmedikament
28.03.25		Zurückhaltung in New York: Dow Jones präsentiert sich am Mittag schwächer